#China #Shenzhen #biopharmaceuticals #Kexing Biopharm #IQVIA

Kexing Biopharm and IQVIA's Strategic Partnership

In a notable move towards enhancing its global footprint, Kexing Biopharm (688136.SH) has officially established a strategic partnership with IQVIA (NYSE: IQV), a recognized leader in clinical research services worldwide. This collaboration, announced on August 11, 2025, sets the stage for accelerating Kexing’s clinical development, regulatory approval, and commercialization of innovative medicines and biosimilars, with prime focus on the European market and other regulated international markets.

The Ambitious Move Towards Globalization

Over recent years, Kexing Biopharm has made substantial strides towards internationalization. It has built a unique globalization platform that integrates advanced R&D capabilities with agile commercial execution. The company has successfully facilitated the entry of multiple high-quality pharmaceutical products into foreign markets. One notable product is nab-paclitaxel, which has already received expedited approval and launched in several key jurisdictions.

In parallel to this, Kexing has been rapidly advancing its R&D portfolio, concentrating on critical therapeutic areas such as antiviral treatments, oncology, immunosuppressants, and metabolic diseases. The focus on these domains underscores Kexing’s commitment to tackling some of the most pressing health challenges globally.

Harnessing Collaboration for Enhanced Efficiency

This strategic partnership leverages IQVIA’s extensive expertise in global clinical trial design, regulatory strategies, and data-driven insights. By combining Kexing’s innovative product lineup with IQVIA's operational infrastructure, both organizations aim to streamline clinical trial efficiency and enable faster access to international markets. The collaboration is projected to significantly enhance Kexing’s global development capabilities and accelerate its transformation into an international biopharmaceutical innovator.

During the signing ceremony, Brian Mi, the president of IQVIA Asia-Pacific, emphasized Kexing's swift progress in foreign market commercialization and innovative products. He stated that this collaboration would open new avenues for both parties. On the other hand, Yanqing Zhao, CEO of Kexing Biopharm, highlighted the essential role of IQVIA’s global clinical data resources, patient insights, and regulatory knowledge in optimizing development strategy, improving success rates, and shortening global registration timelines.

Kexing Biopharm’s Commitment to Innovation

Kexing Biopharm is an innovative biopharmaceutical company primarily dedicated to the R&D, production, and sales of recombinant protein-based drugs and microbiological preparations. The company's specialization includes antiviral therapies, tumor treatment, autoimmune diseases, metabolic disorders, degenerative diseases, and other therapeutic areas. Kexing aspires to create cutting-edge biotechnological platforms for new proteins, antibodies, nucleic acids, and other drug types.

Adhering to a development model of “innovation + internationalization” based on their platforms, Kexing is also exploring broader applications of biotechnology in the healthcare sector. This strategic alliance reflects Kexing Biopharm's long-term commitment to international expansion through scientific rigor, effective execution, and strong partnerships.

Going forward, Kexing intends to deepen its global collaborations to make high-quality Chinese pharmaceutical innovations available to patients worldwide. As the industry landscape continues to evolve, this partnership with IQVIA sets a promising precedent for advancing Kexing’s goals in the biopharmaceutical domain, paving the way for future innovations and patient-centric solutions.